COVID-19: Vaccines and Therapeutics
The Centers for Medicare & Medicaid Services (CMS) today released updated guidance for compliance with the agency’s COVID-19 vaccination requirement for health care staff.
Beginning today through the end of the public health emergency, the free tests are available through eligible health care providers and pharmacies.
Three more regions are no longer authorized to treat patients at high risk for progressing to severe COVID-19 with sotrovimab because the monoclonal antibody is unlikely to work against the BA.2 variant predominating there.
Cardiac complications after SARS-CoV-2 infection or mRNA COVID-19 vaccination are low overall but higher after infection than after vaccination, according to an analysis of electronic health record data.
In a new study released by the Centers for Disease Control and Prevention, adults who received a Pfizer or Moderna booster after the J&J vaccine were better protected than those who received one or two J&J doses.
The Food and Drug Administration today authorized, and CDC recommended, a second Pfizer or Moderna COVID-19 vaccine booster dose for adults aged 50 and older and certain immunocompromised individuals.
The Food and Drug Administration last week revised its emergency use authorization for the monoclonal antibody sotrovimab to exclude regions where the COVID-19 omicron BA.2 subvariant predominates.
Photo Credit: WVU Medicine
Moderna yesterday asked the Food and Drug Administration to authorize a second booster dose of its COVID-19 vaccine for adults age 18 and older who received an initial booster of any authorized or approved COVID-19 vaccine.
Studies show benefits of mRNA vaccines, boosters.